Document Detail


Clinical impact of identifying lactose maldigestion or fructose malabsorption in irritable bowel syndrome or other conditions.
MedLine Citation:
PMID:  19738525     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The role of carbohydrate maldigestion or malabsorption remains unclear in patients with irritable bowel syndrome (IBS). The purpose of this study was to examine the impact of identifying lactose maldigestion (LM) and fructose malabsorption (FM) on patients with and without IBS. METHODS: Patients who received lactose and fructose challenge testing formed the study group. Carbohydrate challenge testing was performed with 50 g lactose and 25 g fructose. Breath samples were collected and analyzed for hydrogen, methane, and CO2 (for correction) using a MicroLyzer Model SC (QuinTron Instrument Company, Milwaukee, WI). Questionnaires were used to assess Rome III IBS criteria, compliance with carbohydrate dietary modifications, and changes in symptoms. RESULTS: One hundred and twenty-one of the 181 (67%) study subjects were able to be contacted 8 months to 4 years after carbohydrate testing. LM (21) and FM (2) were seen in 33% of the 66 IBS subjects. LM (12) and FM (9) were seen in 33% of the 55 subjects without IBS. Seventy-seven percent of IBS and 72% of those without IBS reported compliance with dietary advice. Of the subjects who reported compliance, 47% of IBS and 77% of those without IBS reported that, after identifying LM or FM, their symptoms resolved or improved. CONCLUSIONS: Carbohydrate maldigestion has a similar incidence in patients with and without IBS and both populations have similar compliance with therapeutic diets. However, patients without IBS are more likely to have improvement in symptoms when dietary changes are instituted when compared to IBS patients.
Authors:
Meredith Corlew-Roath; Jack A Di Palma
Related Documents :
17611915 - Prospective multicenter trial of capsule endoscopy in patients with chronic abdominal p...
4834885 - Dermatitis herpetiformis. immunologic concomitants of small intestinal disease and rela...
18422815 - Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical ...
9669625 - Spectral analysis of heart rate variability in patients with irritable bowel syndrome.
20977565 - Itpa gene variant protects against anemia induced by pegylated interferon-α and ribavi...
25255745 - Hypochromic vitiligo: delineation of a new entity.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Southern medical journal     Volume:  102     ISSN:  1541-8243     ISO Abbreviation:  South. Med. J.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-11-02     Completed Date:  2009-12-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0404522     Medline TA:  South Med J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1010-2     Citation Subset:  AIM; IM    
Affiliation:
Division of Gastroenterology, University of South Alabama College of Medicine, Mobile, Alabama 36693, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Breath Tests
Female
Follow-Up Studies
Fructose / diagnostic use,  pharmacokinetics*
Humans
Intestinal Absorption / physiology*
Irritable Bowel Syndrome / diet therapy,  physiopathology*
Lactose / diagnostic use
Lactose Intolerance / physiopathology*
Male
Patient Compliance
Sweetening Agents / diagnostic use
Treatment Outcome
Chemical
Reg. No./Substance:
0/Sweetening Agents; 30237-26-4/Fructose; 63-42-3/Lactose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Celiac disease associated with dilated cardiomyopathy.
Next Document:  Vitamin deficiency after gastric bypass surgery: a review.